coin-img-ETHETH+2.44%coin-img-BTCBTC+1.03%coin-img-SOLSOL+0.77%coin-img-USDCUSDC+0.01%coin-img-XRPXRP-0.82%coin-img-TRXTRX+0.36%coin-img-BNBBNB+0.44%coin-img-HYPEHYPE+3.60%coin-img-ETHETH+2.44%coin-img-BTCBTC+1.03%coin-img-SOLSOL+0.77%coin-img-USDCUSDC+0.01%coin-img-XRPXRP-0.82%coin-img-TRXTRX+0.36%coin-img-BNBBNB+0.44%coin-img-HYPEHYPE+3.60%coin-img-ETHETH+2.44%coin-img-BTCBTC+1.03%coin-img-SOLSOL+0.77%coin-img-USDCUSDC+0.01%coin-img-XRPXRP-0.82%coin-img-TRXTRX+0.36%coin-img-BNBBNB+0.44%coin-img-HYPEHYPE+3.60%coin-img-ETHETH+2.44%coin-img-BTCBTC+1.03%coin-img-SOLSOL+0.77%coin-img-USDCUSDC+0.01%coin-img-XRPXRP-0.82%coin-img-TRXTRX+0.36%coin-img-BNBBNB+0.44%coin-img-HYPEHYPE+3.60%
user-avatar
Barchart

Eli Lilly teams up with CVS to expand weight-loss drug access, cut telehealth visit fees to $29

AI Market Summary
Eli Lilly's DTC collaboration with CVS expands retail distribution for Zepbound/Foundayo and cuts telehealth visit costs to $29, which could improve access and prescription fill rates across CVS's 9,000 pharmacies. The announcement coincides with a strong Q2 beat (revenue +48% y/y) and raised full-year guidance, reinforcing demand momentum in obesity and diabetes franchises and supporting near-term equity sentiment.
Impact level
● Medium
Affected assets
NCSKLLY2USD/USDT+4.14%
AI Insight · NCSKLLY2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Eli Lilly has partnered with CVS to broaden retail access for its weight-loss drugs and reduce telehealth consultation fees to $29, a move expected to lift prescription volumes. The company reported 48% year-on-year revenue growth in Q2, led by $4.93 billion in sales from Zepbound. Eli Lilly also issued strong full-year guidance. Shares have risen more than 35% from their April low.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.